News & Updates

Show Multimedia Only
COVID-linked MIS-C outcomes reassuring at 6 months

COVID-linked MIS-C outcomes reassuring at 6 months

31 Jan 2025
Dupilumab-associated ocular surface disease less common in children, teens with AD

Dupilumab-associated ocular surface disease less common in children, teens with AD

18 Jan 2025